Literature DB >> 20062902

The importance of HIV antenatal screening programs for pregnant women.

Ali A Al-Jabri1, Zakaryia K Al-Muharrami, Abdullah A Balkhair, Shyam S Ganguly.   

Abstract

OBJECTIVE: To investigate retrospectively the prevalence of human immunodeficiency virus (HIV)-1 and 2 among pregnant women during a 10-year period.
METHODS: The total number of pregnant women attending the Sultan Qaboos University Hospital (SQUH), Muscat, Oman between January 1995 and December 2005 was 11553 women. Their age range was 16-45 years (average of 28.67.6 years). The women were tested for HIV-1 and 2 using the standard enzyme-linked immunosorbent assay (ELISA). Positive samples were further tested by Western Blot. The data were statistically analyzed using the Statistical Package for Social Sciences Version 10.0.
RESULTS: By ELISA testing, 21 women were positive for HIV-1 (prevalence rate: 0.2%) and 3 women were weakly positive for HIV-1 (24 women; 0.2% prevalence rate). However, 15 women were confirmed HIV-1 positive using the Western Blot method (prevalence rate: 0.13%) with an average of 1.5 positive women per year. None of the women were found positive for HIV-2.
CONCLUSION: This relatively high prevalence of HIV-1 among pregnant women attending SQUH, highlights the need for screening all pregnant women attending different hospitals and antenatal clinics in Oman. This is essential for preventing the transmission of HIV-1 and 2 to the infants and to the community, and for the appropriate medical treatment and counseling of affected women.

Entities:  

Mesh:

Year:  2010        PMID: 20062902

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  1 in total

1.  HIV and Pregnancy: A Retrospective Descriptive Cross-sectional Study of Prevalence, Maternal, Obstetrical, and Neonatal Outcome at a Tertiary Care Hospital in Oman.

Authors:  Nada Ali Salim Al Hasani; Tamima Al Dughaishi; Abdullah A Balkhair
Journal:  Oman Med J       Date:  2021-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.